- Conditions
- Clinical Stage IV Cutaneous Melanoma AJCC v8, Locally Advanced Melanoma, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Unresectable Melanoma
- Interventions
- Dabrafenib mesylate, Hydroxychloroquine, Placebo Administration, Trametinib dimethyl sulfoxide
- Drug
- Lead sponsor
- ECOG-ACRIN Cancer Research Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 199
- States / cities
- Anchorage, Alaska • Phoenix, Arizona • Scottsdale, Arizona + 139 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 35
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Herpes Labialis
- Interventions
- Squaric Acid solution, Placebo solution
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Melanoma (Skin)
- Interventions
- incomplete Freund's adjuvant, multi-epitope melanoma peptide vaccine, sargramostim, tetanus toxoid helper peptide, dimethyl sulfoxide, imiquimod, adjuvant therapy
- Biological · Drug · Procedure
- Lead sponsor
- Craig L Slingluff, Jr
- Other
- Eligibility
- 12 Years to 120 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
- Interventions
- Trametinib Dimethyl Sulfoxide
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2027
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- SARS-CoV-2
- Interventions
- Upamostat, Placebo (PO)
- Drug
- Lead sponsor
- Henry M. Jackson Foundation for the Advancement of Military Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 92 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 3
- States / cities
- Baltimore, Maryland • Cleveland, Ohio • Nashville, Tennessee
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
- Interventions
- Trametinib Dimethyl Sulfoxide
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2027
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Crohn's Disease
- Interventions
- Prochymal™ adult human mesenchymal stem cells, adult human mesenchymal stem cells
- Drug
- Lead sponsor
- Mesoblast, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006
- U.S. locations
- 4
- States / cities
- Baton Rouge, Louisiana • Charlotte, North Carolina • Pittsburgh, Pennsylvania + 1 more
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
- Interventions
- Trametinib Dimethyl Sulfoxide
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2026
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Anaplastic Astrocytoma, Anaplastic Astrocytoma, Not Otherwise Specified, Anaplastic Ganglioglioma, Anaplastic Pleomorphic Xanthoastrocytoma, Glioblastoma, Malignant Glioma, WHO Grade 3 Glioma, WHO Grade 4 Glioma
- Interventions
- Biospecimen Collection, Dabrafenib Mesylate, Lumbar Puncture, Magnetic Resonance Imaging, Radiation Therapy, Trametinib Dimethyl Sulfoxide
- Procedure · Drug · Radiation
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 3 Years to 25 Years
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 130
- States / cities
- Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 106 more
- Conditions
- BRAF V600 Mutation, Low-grade Glioma, Low Grade Glioma of Brain, Recurrent Low Grade Glioma
- Interventions
- Dabrafenib, Trametinib, Magnetic Resonance Imaging (MRI), Specimen Collection, Optional Lumbar puncture
- Drug · Procedure
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 12 Months to 25 Years
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 7 more
- Conditions
- Cardiac Surgery
- Interventions
- Human platelets
- Biological
- Lead sponsor
- Cellphire Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 161 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • Aurora, Colorado • Washington D.C., District of Columbia + 12 more
- Conditions
- Tinnitus
- Interventions
- DMSO-based otic solution with betahistine, dexamethasone, and lidocaine, DMSO-based transdermal cream with levocarnitine and N-acetylcysteine
- Drug
- Lead sponsor
- Leading Edge Clinic
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Ithaca, New York
- Conditions
- Hematopoietic and Lymphoid Cell Neoplasm, Locally Advanced Malignant Solid Neoplasm, Locally Advanced Melanoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Malignant Solid Neoplasm, Unresectable Melanoma
- Interventions
- Biopsy, Biospecimen Collection, Computed Tomography, Dabrafenib Mesylate, Magnetic Resonance Imaging, Trametinib Dimethyl Sulfoxide, Uprosertib
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2023
- U.S. locations
- 16
- States / cities
- Los Angeles, California • San Francisco, California • Aurora, Colorado + 9 more
- Conditions
- Overactive Bladder, Detrusor Instability, Detrusor Hyperreflexia
- Interventions
- Botulinum-A toxin, Dimethyl sulfoxide (DMSO)
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Erdheim-Chester Disease
- Interventions
- Dabrafenib Mesylate, Quality-of-Life Assessment, Questionnaire Administration, Trametinib Dimethyl Sulfoxide
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Cancer
- Interventions
- Dabrafenib, Trametinib
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 177 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2021
- U.S. locations
- 15
- States / cities
- Los Angeles, California • Orange, California • Aurora, Colorado + 11 more
- Conditions
- Cellular Injury and Post-Cryogenic Recovery, Cryogenic Cellular Stress, Cold-Induced Cellular Injury, Thermal Injury Response, Post-Thaw Viability Impairment, Osmotic Stress Injury, Biomechanical Injury Modeling (In-Vitro), Blunt Force Injuries to the Extremities (Cellular Injury Model), Tissue Damage and Recovery Pathways, Hypothermic Tissue Stress, Cellular Regeneration and Repair
- Interventions
- Standard Laboratory Cryopreservation Procedure, Enhanced Laboratory Cryopreservation Procedure, Normothermic Cell Culture Control
- Other
- Lead sponsor
- Truway Health, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2066
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Myelodysplastic Syndromes, Myelofibrosis, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Refractory Hodgkin Lymphoma, Relapsed Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia, Lymphoid Malignancies, Chronic Myelogenous Leukemia
- Interventions
- cyclophosphamide, fludarabine phosphate, total-body irradiation, cyclosporine, mycophenolate mofetil, umbilical cord blood transplantation, mesenchymal stem cell transplantation
- Drug · Radiation · Procedure
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Organ Dysfunction, Hemolysis
- Interventions
- Not listed
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 10 Years to 80 Years
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2015
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Ovarian Cancer, Ovarian Neoplasms
- Interventions
- Vigil, Placebo
- Biological · Other
- Lead sponsor
- Gradalis, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 92 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2028
- U.S. locations
- 26
- States / cities
- Mobile, Alabama • Irvine, California • San Francisco, California + 22 more
- Conditions
- Stroke, Stroke, Acute, Brain Injury, Acute
- Interventions
- Umbilical Cord Blood, Placebo
- Biological · Other
- Lead sponsor
- Joanne Kurtzberg, MD
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 79 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 6
- States / cities
- Aurora, Colorado • Gainesville, Florida • Atlanta, Georgia + 3 more
- Conditions
- Adult Solid Neoplasm
- Interventions
- Gamma-Secretase Inhibitor RO4929097, Ketoconazole, Rifampin, Midazolam Hydrochloride, Omeprazole, Tolbutamide, Dextromethorphan Hydrobromide, Pharmacological Study, Laboratory Biomarker Analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Overactive Bladder, Urinary Urge Incontinence, Urinary Incontinence, Detrusor Hyperreflexia, Urge Incontinence
- Interventions
- Botox Instillation, DMSO Instillation
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Low Grade Glioma (LGG) of Brain With BRAF Aberration, High Grade Glioma (HGG) of the Brain With BRAF Aberration, Low Grade Glioma of Brain With Neurofibromatosis Type 1
- Interventions
- Dabrafenib, Trametinib, Hydroxychloroquine
- Drug
- Lead sponsor
- Pediatric Brain Tumor Consortium
- Network
- Eligibility
- 1 Year to 30 Years
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 15
- States / cities
- Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 12 more